Celularity (CELU) Net Cash Flow Growth (1y) (2020 - 2025)
Celularity (CELU) Net Cash Flow Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 846.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 846.90% |
| Sep 30, 2025 | -205.38% |
| Jun 30, 2025 | 145.34% |
| Mar 31, 2025 | -137.70% |
| Dec 31, 2024 | 113.09% |
| Sep 30, 2024 | 92.07% |
| Jun 30, 2024 | 74.41% |
| Mar 31, 2024 | 132.78% |
| Dec 31, 2023 | 82.79% |
| Sep 30, 2023 | -160.37% |
| Jun 30, 2023 | 45.73% |
| Mar 31, 2023 | -150.47% |
| Dec 31, 2022 | 18.90% |
| Sep 30, 2022 | -92.78% |
| Jun 30, 2022 | 33.92% |
| Mar 31, 2022 | 134.36% |
| Dec 31, 2021 | -33.34% |
| Sep 30, 2021 | 230.07% |
| Jun 30, 2021 | -7,274.29% |
| Mar 31, 2021 | -7,520.18% |